BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 23325880)

  • 21. [Clinical trials in children--between the expectations of scientific requirements, the assurance of proven treatment and ethical demands].
    Lehmann B; Mentzer D; Fischer T; Mallinckrodt-Pape K
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2009 Apr; 52(4):410-6. PubMed ID: 19266173
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Germany opposes EU plans for regulating clinical trials owing to lack of ethical standards.
    Tuffs A
    BMJ; 2012 Oct; 345():e6640. PubMed ID: 23033377
    [No Abstract]   [Full Text] [Related]  

  • 23. Compounding risks to patients: selective disclosure is not an option.
    McGoey L
    Am J Bioeth; 2009 Aug; 9(8):35-6. PubMed ID: 19998156
    [No Abstract]   [Full Text] [Related]  

  • 24. Lack of proportionality. Seven specifications of public interest that override post-approval commercial interests on limited access to clinical data.
    Strech D; Littmann J
    Trials; 2012 Jul; 13():100. PubMed ID: 22747684
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Is the conflict of interest unacceptable when drug companies conduct trials on their own drugs? No.
    Lawton V
    BMJ; 2009 Nov; 339():b4953. PubMed ID: 19946144
    [No Abstract]   [Full Text] [Related]  

  • 26. How pharmacogenomics will impact the federal regulation of clinical trials and the new drug approval process.
    Binzak BA
    Food Drug Law J; 2003; 58(1):103-27. PubMed ID: 12739592
    [No Abstract]   [Full Text] [Related]  

  • 27. Open clinical trials.
    Drazen JM; Morrissey S; Curfman GD
    N Engl J Med; 2007 Oct; 357(17):1756-7. PubMed ID: 17914035
    [No Abstract]   [Full Text] [Related]  

  • 28. Managing conflicts of interest: a survival guide for biotechs.
    Werner MJ; Price E
    Nat Biotechnol; 2007 Feb; 25(2):161-3. PubMed ID: 17375384
    [TBL] [Abstract][Full Text] [Related]  

  • 29. European Clinical Trials Directive: responses made to MHRA consultation letter MLX 287.
    Flavell DJ; Flavell SU; Sullivan R
    Lancet; 2003 Oct; 362(9393):1415. PubMed ID: 14585646
    [No Abstract]   [Full Text] [Related]  

  • 30. The ongoing regulation of generic drugs.
    Frank RG
    N Engl J Med; 2007 Nov; 357(20):1993-6. PubMed ID: 18003956
    [No Abstract]   [Full Text] [Related]  

  • 31. Patent protection for medical technologies: why some and not others?
    Melzer D
    Lancet; 1998 Feb; 351(9101):518-9. PubMed ID: 9482467
    [No Abstract]   [Full Text] [Related]  

  • 32. India pressed to relax rules on clinical trials. Drug companies claim changes are essential, but critics fear Indian patients will become guinea pigs.
    Sharma DC
    Lancet; 2004 May; 363(9420):1528-9. PubMed ID: 15139330
    [No Abstract]   [Full Text] [Related]  

  • 33. Disclosure of adverse clinical trial results--should legal immunity be granted to drug companies?
    Vernillo A
    Am J Bioeth; 2009 Aug; 9(8):45-7. PubMed ID: 19998162
    [No Abstract]   [Full Text] [Related]  

  • 34. Unlocking Health Canada's cache of trade secrets: mandatory disclosure of clinical trial results.
    Herder M
    CMAJ; 2012 Feb; 184(2):194-9. PubMed ID: 21876028
    [No Abstract]   [Full Text] [Related]  

  • 35. Drive for drugs leads to baby clinical trials.
    Nature; 2006 Mar; 440(7083):406-7. PubMed ID: 16554774
    [No Abstract]   [Full Text] [Related]  

  • 36. Seroxat and the suppression of clinical trial data: regulatory failure and the uses of legal ambiguity.
    McGoey L; Jackson E
    J Med Ethics; 2009 Feb; 35(2):107-12. PubMed ID: 19181884
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Medicines regulation and the pharmaceutical industry.
    Breckenridge A; Woods K
    BMJ; 2005 Oct; 331(7520):834-6. PubMed ID: 16210285
    [TBL] [Abstract][Full Text] [Related]  

  • 38. FDA says it's open to new approaches to cancer trials.
    Traynor K
    Am J Health Syst Pharm; 2008 May; 65(9):795, 800. PubMed ID: 18436724
    [No Abstract]   [Full Text] [Related]  

  • 39. A precarious balancing act--the role of the FDA as protector of public health and industry wealth.
    McCabe AR
    Suffolk Univ Law Rev; 2003; 36(3):787-819. PubMed ID: 16493844
    [No Abstract]   [Full Text] [Related]  

  • 40. Experimental use and the Orphan Drug Act: a biotechnology conundrum.
    Koivuniemi PJ
    Nat Biotechnol; 1996 Apr; 14(4):511-2. PubMed ID: 9630930
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.